WallStSmart

Concentra Group Holdings Parent, Inc. (CON)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2905% more annual revenue ($65.01B vs $2.16B). MRK leads profitability with a 28.1% profit margin vs 7.7%. MRK trades at a lower P/E of 15.2x. MRK earns a higher WallStSmart Score of 59/100 (C).

CON

Buy

59

out of 100

Grade: C

Growth: 8.0Profit: 7.0Value: 7.7Quality: 4.8
Piotroski: 2/9

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CONUndervalued (+66.5%)

Margin of Safety

+66.5%

Fair Value

$72.22

Current Price

$22.47

$49.75 discount

UndervaluedFair: $72.22Overvalued
MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$110.95

$14.47 premium

UndervaluedFair: $96.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CON4 strengths · Avg: 9.0/10
Return on EquityProfitability
48.1%10/10

Every $100 of equity generates 48 in profit

EPS GrowthGrowth
60.1%10/10

Earnings expanding 60.1% YoY

P/E RatioValuation
17.4x8/10

Attractively priced relative to earnings

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

CON2 concerns · Avg: 3.0/10
Profit MarginProfitability
7.7%3/10

7.7% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : CON

The strongest argument for CON centers on Return on Equity, EPS Growth, P/E Ratio. Revenue growth of 15.9% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bear Case : CON

The primary concerns for CON are Profit Margin, Piotroski F-Score.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CON profiles as a growth stock while MRK is a value play — different risk/reward profiles.

CON is growing revenue faster at 15.9% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CON scores higher overall (59/100 vs 59/100) and 15.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Concentra Group Holdings Parent, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company that specializes in acquiring and managing businesses in high-growth sectors such as healthcare, technology, and infrastructure. With a commitment to operational excellence and innovation, Concentra leverages its seasoned leadership team to enhance portfolio performance through strategic investments and proactive management. This forward-looking approach positions the company to effectively capitalize on emerging trends and opportunities, making it an attractive investment for institutional investors aiming to diversify into high-potential industries.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?